"Clinical Innovation: Fair and Effective Incentives for New Uses of…
Michael Eder advises German and foreign clients in all aspects of intellectual property, with an emphasis in the areas of pharmaceuticals, protein biochemistry, and industrial chemistry. His scientific background includes the fields of biophysical, organic und inorganic chemistry, as well as molecular biology. An important part of his practice relates to the drafting, prosecution and coordination of European and German patent applications, particularly in the area of pharmaceutical chemistry and protein biochemistry. Dr. Eder is furthermore responsible for numerous opposition proceedings before the EPO and has been involved in a number of national and multinational patent litigation cases. Another main focus of his work lies in rendering patent validity and infringement opinions in connection with freedom-to-operate und due diligence projects, as well as counselling clients in matters relating to supplementary protection certificates (SPCs) for pharmaceuticals in Europe.
- German Patent Attorney
- European Patent Attorney
- European Trademark Attorney
- European Design Attorney
references and activities.
- Author and co-author of numerous scientific publications in the field of protein biochemistry:Publications
- Invited speaker at various international patent conferences und workshops
- In 2013 Dr. Michael Eder was recommended by Global Law Experts as an expert for patent law in Germany.
- Teva GmbH vs. OSI Pharmaceuticals & Pfizer Products Inc.: represented Teva in a nullity action against the EP patent relating to Pfizer’s blockbuster anti-cancer drug Erlotinib / Tarceva®
- Sandoz AG vs. Bristol-Myers Squibb (BMS) Holdings Ireland: representing Intervener (Sandoz) in EPO Opposition Proceedings in connection with Infringement / Arbitration Proceedings in Portugal
- Teva Pharmaceutical Industries Ltd. (Israel) vs. Gilead Sciences, Inc. (USA): representing Teva in 5 Oppositions against Cobicistat base patent (EP 2 049 506 and 4 divisionals)
- Teva Pharmaceutical Industries Ltd. (Israel) vs. Hoffmann La Roche (Switzerland): representing in Opposition against Erlotinib Polymorph Patent (EP 1 597 239 B1)
- Lonza Ltd. (Switzerland) vs. Sangamo Biosciences, Inc. (USA): Representing Lonza in EPO Opposition Proceedings against EP 2 281 050 B1
- “Characterization of human and pig kidney long-chain-acyl-CoA dehydrogenases and their role in β-oxidation”, M. Eder, F. Kräutle, Y. Dong, P. Vock, V. Kieweg, J.J.-P. Kim, A. W. Strauss, and S. Ghisla; Eur J Biochem 245: 600-607, (1997).
- “Substrate activation by acyl-CoA dehydrogenases: transition-state stabilization and pKs of involved functional groups”, P. Vock, S. Engst, M. Eder, S. Ghisla; Biochemistry 37: 1848-1860, (1998).
- “Functional aspects of the X-ray structure of mitochondrial creatine kinase: a molecular physiology approach” U. Schlattner, M. Forstner, M. Eder, O. Stachowiak, K. Fritz-Wolf, T. Wallimann; Mol Cell Biochem 184: 125-140, (1998)
- “Creatine kinase: an enzyme with a central role in cellular energy metabolism.” T. Wallimann, M. Dolder, U. Schlattner, M. Eder, T. Hornemann, T. Kraft, M. Stolz; MAGMA 6: 116-119, (1998).
- “Some new aspects of creatine kinase (CK): compartmentation, structure, function and regulation for cellular and mitochondrial bioenergetics and physiology.” T. Wallimann, M. Dolder, U. Schlattner, M. Eder, T. Hornemann, E. O’Gorman, A. Rück, D. Brdiczka; Biofactors 8 :229-234, (1998).
- “Crystal structure of brain-type creatine kinase at 1.41Å resolution” M. Eder, U. Schlattner, A. Becker, T. Wallimann, W. Kabsch, K. Fritz-Wolf; Prot. Sci., Nov, 8 (11): 2258-69, (1999)
- “Crystal structure of human ubiquitous mitochondrial creatine kinase”M. Eder, K. Fritz-Wolf, W. Kabsch, T. Wallimann, U. Schlattner; Proteins, May 15; 39(3): 216-25, (2000)
- “A conserved negatively charged cluster in the active site of creatine kinase is critical for enzymatic activity” M. Eder, M. Stolz, T. Wallimann; U. Schlattner; J. Biol. Chem., Sep 1; 275(35): 27094-9, (2000)
- “Divergent enzyme kinetics and structural properties of the two human mitochondrial creatine kinase isoenzymes” U. Schlattner, M. Eder, M., Dolder, Z.A. Khuchua, A.W. Strauss, T. Wallimann; Biol. Chem., Nov; 381(11): 1063-70, (2000)